Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction ，a Phase II Clinical Study
Conditions: Gastric Cancer; GastroEsophageal Cancer; Adenocarcinoma Interventions: Drug: Sintilimab,nab-paclitaxel and tegio Sponsors: Wu Jun Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
Conditions: Advanced Gastric Adenocarcinoma Interventions: Drug: Apatinib Combined With Tislelizumab and Chemotherapy Sponsors: Renmin Hospital of Wuhan University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma
Conditions: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Interventions: Drug: irinotecan; Drug: IBI343; Drug: paclitaxel Sponsors: Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)
Conditions: Prostate Adenocarcinoma; Localized Prostate Carcinoma Interventions: Procedure: Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy （VIP） techniques; Procedure: Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques Sponsors: Shanghai Changzheng Hospital; Shanghai Zhongshan Hospital; ShuGuang Hospital; The Third Affiliated Hospital of Naval Medical University; The First Affiliated Hospital of Guangzhou Medical University; Sir Run Run Shaw Hospital; Sichuan Provincial People ' s Hospital Recr...
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Conditions: Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8 Interventions: Biological: Anti-STEAP1 CAR T-cells; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Bone Scan; Procedure: Computed Tomography; Drug: Cyclophosphamide; Procedure: Echocardiography; Drug: Enzalutamide; Drug: Fludarabine; Procedure: Leukapheresis; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Procedure: Positron Emission Tomography Sponsors: Fred Hutchinson Cancer Center; PromiCell Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care
Conditions: Small Bowel Adenocarcinoma Sponsors: Copenhagen University Hospital at Herlev; Aarhus University Hospital; Rigshospitalet, Denmark; University of Copenhagen Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
Conditions: Breast Cancer; Breast Neoplasms; Breast Adenocarcinoma; Breast Cancer Stage; Breast Cancer Stage IV; Breast Cancer Invasive; Breast Cancer in Situ Sponsors: Medical College of Wisconsin Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Copper Cu 64 PSMA I & T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
Conditions: Prostate Cancer; Prostate Adenocarcinoma; Biochemical Recurrence of Malignant Neoplasm of Prostate Interventions: Drug: Copper Cu 64 PSMA I&T Sponsors: Curium US LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Copper Cu 64 PSMA I & T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Conditions: Prostate Cancer; Prostate Adenocarcinoma Interventions: Drug: Copper Cu 64 PSMA I&T Sponsors: Curium US LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma
Conditions: Metastatic Pancreatic Adenocarcinoma Interventions: Combination Product: Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA); Combination Product: Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA); Combination Product: Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA) Sponsors: Chang Gung Memorial Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
Conditions: Metastatic Adenocarcinoma of the Pancreas Interventions: Drug: Irinotecan liposome injection (S095013); Drug: Oxaliplatin; Drug: LLV (levoisomer form of leucovorin); Drug: 5- FU (5-Fluorouracil) Sponsors: Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer
Conditions: Colorectal Adenocarcinoma Interventions: Drug: Fluoxetine Sponsors: Jonsson Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
Conditions: Gastric Cancer; Adenocarcinoma of Esophagogastric Junction Interventions: Drug: Anlotinib; Drug: TQB2450; Drug: Albumin-Bound Paclitaxel Sponsors: Peking University; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Conditions: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma Interventions: Drug: Disitamab Vedotin Injection; Drug: Cadonilimab Injection; Drug: Paclitaxel Injection Sponsors: RemeGen Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials
Multicenter Observational Study Taul í-T1 Classification for the Management of pT1 Rectal Adenocarcinoma
Conditions: Rectal Cancer Stage I Interventions: Diagnostic Test: Taul í-T1 versus conventional classifications Sponsors: Corporacion Parc Tauli Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials
